DEVON, Pa., June 26, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has been added to the Russell 3000® Index as part of the FTSE’s annual reconstitution of its family of U.S. indexes. The addition will take effect after the U.S. market opens on June 26.
Annual Russell index reconstitution captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity universe. The index is a subset